South Africa is one of only six countries to ever meet their “fair share target” for funding tuberculosis (TB) research, according to a new report. In absolute terms however, South Africa’s contribution is small change compared to investments into TB research made by the top two contributors, the United States government and the Bill and Melinda Gates Foundation. Catherine Tomlinson unpacks what the report tells us about investment in TB research in South Africa.
In 2001, at age 22, Vuyiseka Dubula-Majola joined the Treatment Action Campaign in its fight to bring antiretrovirals to South Africa. Today, she walks the streets of Geneva in Switzerland to get to her job as head of the Global Fund’s community, rights and gender department. Biénne Huisman spoke with Dubula-Majola about her remarkable journey, balancing activism with diplomacy, and the struggle “to build and regain the dignity of poor people around the globe”.
It is estimated that over 65% of the global HIV burden is in sub-Saharan Africa. Now, in an attempt to propel African voices and perspectives in the next phase of the HIV response in Africa, a group of Africans established an African-led HIV control working group (HCWG). They are all experts from the continent who have come together to develop consensus perspectives on the long-term sustained control of HIV and prioritise the systems and capabilities to achieve it. Drs Yogan Pillay and Izukanji Sikazwe explain the thinking behind the new working group and set out their objectives.